Appln. No. 09/786,867 Amdt. dated July 3, 2006 Reply to Office action of April 3, 2006

Amendments to the Drawings

The attached sheet of drawings includes changes to Fig.

5. This sheet replaces the corrected Fig. 5 that was filed on October 20, 2005.

Attachment:

Replacement Sheet

Annotated Sheet Showing Changes

REMARKS

The Office Action has been carefully reviewed. No claim is allowed. Claims 74-82 presently appear in this application and define patentable subject matter warranting their allowance. Reconsideration and withdrawal of the rejection are therefore respectfully solicited.

The examiner indicates that the replacement drawing (Fig. 5) filed with the amendment of October 20, 2005, is not acceptable because the three letter codons CAA and TAT are not correct. The examiner further indicates that Gln138 as shown on Exhibit D is wrong.

The three letter codons CAA and TAT noted in Exhibit B are correct in Fig. 5 but the amino acid residues that they code for are incorrect in Fig. 5. Codons CAA and TAT should correctly code for Gln138 and Tyr132, respectively. The correction of amino acid residues 132 and 138 in Fig. 5 from Thr132 and Glu138 to Tyr132 and Gln138 is shown in the corrected Fig. 5 attached hereto for the examiner's review and approval.

With regard to Exhibit D, the residue at position 138 should be <u>Gln</u>. It is not understood why the examiner is indicating in Exhibit D, page 1 of 2, that Gln at residue position 138, encoded by the codon CAA, is wrong.

The examiner states that the amendment filed January 31, 2005, is objected to because it introduces new matter into

Appln. No. 09/786,867 Amdt. dated July 3, 2006

Reply to Office action of April 3, 2006

the disclosure. The examiner indicates that SEQ ID NO:5 filed in that amendment and the sequence disclosed in PCT/IL99/00485 are not identical and refers to the sequence alignment provided in Exhibit A. This objection is respectfully traversed.

The sequence alignment shown in Exhibit A, page 2 of 2, left column, shows only two differences at residues 132 and 138. While the errors in Fig. 5 is being corrected by the instant amendment, the substitute sequence listing attached to the amendment filed October 20, 2005, correctly identifies residues 132 and 138 as Tyr and Gln, respectively. This is not new matter because the codons for residues 132 and 138 are presented in Fig. 5 and SEQ ID NO:1 as being TAT and CAA, respectively. It is clearly understood by those in the art that codons TAT and CAA code for Tyr and Gln, and not Thr and Glu. Accordingly, there is no matter introduced into the disclosure.

Reconsideration and withdrawal of the objection are therefore respectfully requested.

Claims 70, 77, 79 and 80 have been objected to under 37 CFR 1.75(c), as being of improper dependent form for failing to further limit the subject matter of a previous claim. This objection is obviated by the correction to Fig. 5 and by the sequence listing attached to the amendment filed October 20, 2005. Nucleotides 459-602 of SEQ ID NO:1 does indeed encode

Appln. No. 09/786,867 Amdt. dated July 3, 2006

Reply to Office action of April 3, 2006

residues 118-165 of SEQ ID NO:5 of the sequence listing filed October 5, 2005.

Reconsideration and withdrawal of the objection are therefore respectfully requested.

Claims 67-82 have been rejected under 35 U.S.C. §112, first paragraph, as failing to comply with the written description requirement. The examiner clarified that claims 74-82 are being rejected for new matter. The rejection as it relates to claims 67-73 is obviated by the cancellation of claims 67-73 without prejudice. The rejection as it relates to claims 74-82 is obviated by the showing above that SEQ ID NO:5 merely correctly identifies the three amino acid residues 65, 132 and 138 (discrepancies in Exhibit B) as Glu, Tyr and Gln, respectively, which are encoded by the codons GAA, TAT and CAA of SEQ ID NO:1 (Fig. 5). Accordingly, the correction of residues 65, 132 and 138 to Glu, Tyr and Gln, respectively, in SEQ ID NO:5 is fully supported by the application as originally filed and cannot be considered to be new matter.

Reconsideration and withdrawal of this rejection are therefore respectfully requested.

In view of the above, the claims comply with 35 U.S.C. \$112 and define patentable subject matter warranting their

Appln. No. 09/786,867
Amdt: dated July 3, 2006

Reply to Office action of April 3, 2006

allowance. Favorable consideration and early allowance are earnestly urged.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C. Attorneys for Applicant(s)

ACY:pp

Telephone No.: (202) 628-5197
Facsimile No.: (202) 737-3528
G:\BN\C\cohn\moroz3\pto\2006-07-03amendment.doc

Appln. No. 09/786,867 Amd. Dated July 3, 2006 Reply to Office Action of April 3, 2006 Annotated Sheet Showing Changes

7/15
TIGACACCAGACCAACTEGTAATAGTAGCGACCGGCGCTCAGCTGGAATTGCAAAAAATGT

•				• .			GCCGC	val	arg .	gin
net	tia	thr	ala	zer,	ttur	192	gin		CGC	CAG
TG	ACG	ACC	GCG	TCC .	ACC .	TCE	CAG.	GTG	حاقاب	U , U
		his	gin .	asp .	ser	glu	ala	ais	le .	asn
su .	tyr	•	CAG	GAC	TCA	GAG	GCC	GCC	ATĆ	AAC
AC .	TAC	CAC	CAG.			. .		٠,_ '	,	her.
ng	gtn	De .	asn	jeu .	glu	leu ,	tyr ·	aia	ser TCC	tyr TAC
GC	CAG	ATC	AAC	CTG	GAG	CTC	TAC	GCC	100	120
				. دهــ	SET	tyr	tyr	phe -	asp	erg
al	tyr	leu	ser	met	TCT	TAC	TAC	TIT	GAC	.CGC
शा ्	TAC	CTG	TCC	ATG						_
SĐ	ssp	val	ata	leu	łys	ट्या	phe	ala	lys .	tyr
SAT	GAT '	GTG	GCT	TTG	AAG	AAC	TIT	GCC	AAA	TAC
				į.			głu	ang	glu	his
he	teu	his	द्भा	ser	his o.T	an.	GAG	AGG	GAA	CAT
III	CTT	CAC	CAA	TCT	CAT	GAG		,,,,,		•
:	ando s	lys	leu	met	lys	leu	gtn	250	gin .	ब्रमु
ela cct	gtu GAG	nys AAA	CTG	ATG	AAG	CTG	CAG	AAC	CAA	CGA
GCT	GAG	- Co-co-c	Ţ. .	***	٠			3	lys	tys
gly	gly	ਕਾਰੂ	Вe	phe	jeu	gin	asp	je ATC	AAG	AAA
GGT	GGC	CGA	ATC	TTC	CTT	CAG	GAT	AIC	,,,,,	
				asp	tp	gtu	ser	gly '	jeu	asn
bto	asp	cys TGT	asp GAT	GÀC.	TGG	GAG	AGC	GGG	CTG	AAT.
CCA	GAC	101	٠,,						iya	2SN
sla	med	głu	cys	ala	leu	his	leu	glu GAA	AAA	AAT
GCA	ATG	GAG	TGT	GCA	TTA	CAT	116	LOMM		,
				jeu	leu	glu ·	phe	pro	ser	pro
val .	esn	gin	ser TCA	CTA	CTG	GAA	TTC	ССТ	TCT	CCT
GTG	AAT	CAG	IUM	CIA	٠,٠	•			L?-	±7,7
lle .	ser	pro	ser	bto	56	cys	p.b	his	his	[thr] TAT
ATC	TCT	œ	AGT	. CCT	AGC	TGC	TGG	CAT	CAC	101
					gin	pro	gin	his	his	leu
thr	ttu	257	arg	. pro	[glu]	ĊĊΤ	CAA	CAC	CAC	CTT
ACT	ACT	AAC	AGA	CCG	CAA				_,,_	
leu		pro'	arg .	.arg	erg	lys	arg	pro	his	ser
	CGA	CCC	CGC		AGG	AAG	AGA	<u> </u>	CAT	TCT
CIT	CGA								561	pro
Це	рго	לזר	buo	ile	leu	ile	phe	arg		CCC
ATA	CCA	ACA	CCT	ATT	CTG	ATT	<u> 111</u>	CGG	, , , , , ,	

TGA AGTITATATTCTTATCCTACCAGGCTTCGGAATAATCTCCCATATTGTAACTTAC

TACTCCGGAAATCGCTGTCGCCTAACCGCTAACATTACTGCAGGCCACCTACTCATGCAG

CTAATTGGAAGDGCCACCCTAGCAATATCAACCATTAACCTTCCCTCTACACTTATCATC

TTCACAATTCTAATTCTACTGACTATCCTAGAAATCGCTGTCGCCTTAATCCAAGCCTAC

GTTTCACACTITATION PORTOR OF THE CONTRACT CACAC CACAC CACAC CACACACAC

SUBSTITUTE SHEET (RULE 25)